These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

309 related items for PubMed ID: 21659544

  • 21. ABT-737 is highly effective against molecular subgroups of multiple myeloma.
    Bodet L, Gomez-Bougie P, Touzeau C, Dousset C, Descamps G, Maïga S, Avet-Loiseau H, Bataille R, Moreau P, Le Gouill S, Pellat-Deceunynck C, Amiot M.
    Blood; 2011 Oct 06; 118(14):3901-10. PubMed ID: 21835956
    [Abstract] [Full Text] [Related]

  • 22. YM-155 potentiates the effect of ABT-737 in malignant human glioma cells via survivin and Mcl-1 downregulation in an EGFR-dependent context.
    Jane EP, Premkumar DR, DiDomenico JD, Hu B, Cheng SY, Pollack IF.
    Mol Cancer Ther; 2013 Mar 06; 12(3):326-38. PubMed ID: 23325792
    [Abstract] [Full Text] [Related]

  • 23. BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells.
    Huang S, Sinicrope FA.
    Cancer Res; 2008 Apr 15; 68(8):2944-51. PubMed ID: 18413764
    [Abstract] [Full Text] [Related]

  • 24. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737.
    Del Gaizo Moore V, Brown JR, Certo M, Love TM, Novina CD, Letai A.
    J Clin Invest; 2007 Jan 15; 117(1):112-21. PubMed ID: 17200714
    [Abstract] [Full Text] [Related]

  • 25. Cafestol overcomes ABT-737 resistance in Mcl-1-overexpressed renal carcinoma Caki cells through downregulation of Mcl-1 expression and upregulation of Bim expression.
    Woo SM, Min KJ, Seo BR, Nam JO, Choi KS, Yoo YH, Kwon TK.
    Cell Death Dis; 2014 Nov 06; 5(11):e1514. PubMed ID: 25375379
    [Abstract] [Full Text] [Related]

  • 26. Induction of Noxa sensitizes human colorectal cancer cells expressing Mcl-1 to the small-molecule Bcl-2/Bcl-xL inhibitor, ABT-737.
    Okumura K, Huang S, Sinicrope FA.
    Clin Cancer Res; 2008 Dec 15; 14(24):8132-42. PubMed ID: 19088028
    [Abstract] [Full Text] [Related]

  • 27. Myeloid cell leukemia-1 is an important apoptotic survival factor in triple-negative breast cancer.
    Goodwin CM, Rossanese OW, Olejniczak ET, Fesik SW.
    Cell Death Differ; 2015 Dec 15; 22(12):2098-106. PubMed ID: 26045046
    [Abstract] [Full Text] [Related]

  • 28. Molecular analysis of functional redundancy among anti-apoptotic Bcl-2 proteins and its role in cancer cell survival.
    Eichhorn JM, Alford SE, Sakurikar N, Chambers TC.
    Exp Cell Res; 2014 Apr 01; 322(2):415-24. PubMed ID: 24556425
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. ABT-737 increases tyrosine kinase inhibitor-induced apoptosis in chronic myeloid leukemia cells through XIAP downregulation and sensitizes CD34(+) CD38(-) population to imatinib.
    Airiau K, Mahon FX, Josselin M, Jeanneteau M, Turcq B, Belloc F.
    Exp Hematol; 2012 May 01; 40(5):367-78.e2. PubMed ID: 22240609
    [Abstract] [Full Text] [Related]

  • 32. Discovery of marinopyrrole A (maritoclax) as a selective Mcl-1 antagonist that overcomes ABT-737 resistance by binding to and targeting Mcl-1 for proteasomal degradation.
    Doi K, Li R, Sung SS, Wu H, Liu Y, Manieri W, Krishnegowda G, Awwad A, Dewey A, Liu X, Amin S, Cheng C, Qin Y, Schonbrunn E, Daughdrill G, Loughran TP, Sebti S, Wang HG.
    J Biol Chem; 2012 Mar 23; 287(13):10224-10235. PubMed ID: 22311987
    [Abstract] [Full Text] [Related]

  • 33. Proteasomal degradation of Mcl-1 by maritoclax induces apoptosis and enhances the efficacy of ABT-737 in melanoma cells.
    Pandey MK, Gowda K, Doi K, Sharma AK, Wang HG, Amin S.
    PLoS One; 2013 Mar 23; 8(11):e78570. PubMed ID: 24223823
    [Abstract] [Full Text] [Related]

  • 34. Low expression of pro-apoptotic Bcl-2 family proteins sets the apoptotic threshold in Waldenström macroglobulinemia.
    Gaudette BT, Dwivedi B, Chitta KS, Poulain S, Powell D, Vertino P, Leleu X, Lonial S, Chanan-Khan AA, Kowalski J, Boise LH.
    Oncogene; 2016 Jan 28; 35(4):479-90. PubMed ID: 25893290
    [Abstract] [Full Text] [Related]

  • 35. BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia.
    Del Gaizo Moore V, Schlis KD, Sallan SE, Armstrong SA, Letai A.
    Blood; 2008 Feb 15; 111(4):2300-9. PubMed ID: 18056841
    [Abstract] [Full Text] [Related]

  • 36. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation.
    Chen S, Dai Y, Harada H, Dent P, Grant S.
    Cancer Res; 2007 Jan 15; 67(2):782-91. PubMed ID: 17234790
    [Abstract] [Full Text] [Related]

  • 37. Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice.
    Anstee NS, Bilardi RA, Ng AP, Xu Z, Robati M, Vandenberg CJ, Cory S.
    Cell Death Differ; 2019 Jul 15; 26(7):1316-1331. PubMed ID: 30470795
    [Abstract] [Full Text] [Related]

  • 38. The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib.
    Hikita H, Takehara T, Shimizu S, Kodama T, Shigekawa M, Iwase K, Hosui A, Miyagi T, Tatsumi T, Ishida H, Li W, Kanto T, Hiramatsu N, Hayashi N.
    Hepatology; 2010 Oct 15; 52(4):1310-21. PubMed ID: 20799354
    [Abstract] [Full Text] [Related]

  • 39. Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia.
    Vogler M, Butterworth M, Majid A, Walewska RJ, Sun XM, Dyer MJ, Cohen GM.
    Blood; 2009 Apr 30; 113(18):4403-13. PubMed ID: 19008458
    [Abstract] [Full Text] [Related]

  • 40. c-Myc dependent expression of pro-apoptotic Bim renders HER2-overexpressing breast cancer cells dependent on anti-apoptotic Mcl-1.
    Campone M, Noël B, Couriaud C, Grau M, Guillemin Y, Gautier F, Gouraud W, Charbonnel C, Campion L, Jézéquel P, Braun F, Barré B, Coqueret O, Barillé-Nion S, Juin P.
    Mol Cancer; 2011 Sep 07; 10():110. PubMed ID: 21899728
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.